Endocannabinoids in PTSD Treatment: Meta-Analysis of Cannabis Use in Trauma-Focused Care
Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Cannabis use does not appear to undermine the effectiveness of evidence-based PTSD therapies in this population.
#10 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
What This Study Teaches Us
Trauma-focused treatment for PTSD works better than non-trauma-focused approaches even in people actively using cannabis, with larger reductions in PTSD symptoms across both groups. Alcohol and drug use improvements were similar regardless of treatment type or baseline cannabis use, suggesting that cannabis use does not negate the core benefits of evidence-based PTSD care.
Why This Matters Clinically
Many clinicians hesitate to refer patients with PTSD and active cannabis use to intensive trauma-focused therapies, worrying the treatments won’t work or that cannabis will interfere with gains. This meta-analysis gives permission to offer best-practice PTSD treatment without waiting for cannabis cessation, though it does flag lower attendance rates in the trauma-focused group that deserve attention.
Study Snapshot
| Study Design | Meta-analysis of individual patient data from 4 of 36 RCTs in Project Harmony, a larger dataset on co-occurring PTSD and substance use disorders |
| Population | N = 410 (70% male) with co-occurring PTSD and substance use disorders; 33.2% endorsed baseline cannabis use |
| Intervention | Trauma-focused (TF) versus non-trauma-focused (non-TF) psychosocial treatments; duration and specific modalities not detailed in abstract |
| Primary Outcome | Within-treatment changes in PTSD symptom severity, alcohol use, and non-cannabis drug use severity, plus treatment attendance rates |
| Key Result | Trauma-focused treatment produced larger PTSD symptom reductions than non-trauma-focused regardless of cannabis use, but with lower attendance; alcohol and drug use reductions were similar across all conditions |
Where This Paper Deserves Skepticism
The abstract does not specify which four RCTs were included, their methodologies, or why those four were selected from 36, raising questions about selection bias. The mechanism behind lower attendance in trauma-focused groups is unexplored; this could reflect dropout due to treatment intensity, symptom exacerbation, or unmeasured confounders related to cannabis use. The sample size for the cannabis subgroup (N = 135 with cannabis use) limits statistical power for subgroup interactions, and we cannot determine whether cannabis users who dropped out differed systematically from completers.
Dr. Caplan’s Take
I find this reassuring for practice. The data push back against the clinical folklore that cannabis-using patients cannot tolerate or benefit from trauma work. That said, the attendance gap in trauma-focused conditions is real and shouldn’t be ignored. We need to understand whether that’s a dropout problem (symptom flare, overwhelm), a motivation problem, or something specific to cannabis use dynamics. The study is evidence that we should offer trauma-focused treatment, but not permission to ignore barriers to engagement in this population.
Clinical Bottom Line
Offer trauma-focused PTSD treatment to patients with active cannabis use without waiting for abstinence, as it outperforms alternatives regardless of cannabis status. Expect lower attendance rates in trauma-focused pathways and proactively address barriers to engagement.
| |
Have thoughts on this? Share it:
